Angiogenesis and lymphangiogenesis are key processes during embryogenesis as well as under physiological and pathological conditions. Vascular endothelial growth factor C (VEGFC), the ligand for both VEGFR2 and VEGFR3, is a central lymphangiogenic regulator that also drives angiogenesis. Here we report that members of the highly conserved BACH (BTB and CNC homology) family of transcription factors regulate VEGFC expression, through direct binding to its promoter. Accordingly, downregulation of bach2a hinders blood-vessel formation and impairs lymphatic sprouting in a vegfc-dependent manner during zebrafish embryonic development. In contrast, BACH1-overexpression enhances intratumoral blood-vessel density and peritumoral lymphatic vessel diameter in ovarian and lung mouse tumor models. The effects on the vascular compartment correlate spatially and temporally with BACH1 transcriptional regulation of VEGFC expression. Altogether, our results uncover a novel role for the BACH/VEGFC signaling axis in lymphatic formation during embryogenesis and cancer, providing a novel potential target for therapeutic interventions.
Introduction
The blood and lymphatic networks are two evolutionarily conserved transport systems that provide complementary functions in the maintenance of tissue homeostasis. In particular, the formation of new blood and lymphatic vessels is a prerequisite for vertebrate embryonic and postnatal development. During embryogenesis, the blood circulatory system is first to emerge. As early as mouse embryonic day (E) 7.5, vasculogenesis, the formation of a primitive vascular plexus through proliferation, migration and differentiation of endothelial cells (ECs), takes place. Later on, this plexus undergoes massive remodeling via angiogenesis, which involves also arterio-venous differentiation (A. S. Chung & Ferrara, 2011) . At E10.5, a distinct subpopulation of ECs within the cardinal vein commits to the lymphatic lineage, buds off and migrates to establish primitive lymph sacs, which through further sprouting give rise to the peripheral lymphatic system (Oliver & Alitalo, 2005; Semo, Nicenboim, & Yaniv, 2016) . During adult life, the majority of blood and lymphatic vessels are quiescent, with the exception of female reproductive organs during the ovarian cycle and the placenta during pregnancy. Reactivation of angiogenesis and lymphangiogenesis, however, is a hallmark of pathological processes associated with wound healing, myocardial infarction (MI), allograft rejection, chronic inflammation, tumor progression and malignant cell dissemination (A. S. Chung & Ferrara, 2011; Oliver & Alitalo, 2005) .
The VEGF family of growth factors and its receptors are central signaling pathways, controlling angiogenesis and lymphangiogenesis during development and adulthood. VEGFs exert their activity by binding to the tyrosine kinase receptors (vascular endothelial growth factor receptor-1) VEGFR-1, VEGFR-2, and VEGFR-3, expressed in blood and lymphatic endothelial cells (LECs) (Lohela, Bry, Tammela, & Alitalo, 2009 ). VEGFA, the ligand for VEGFR-1 and VEGFR-2, is best known for its role in angiogenesis, stimulating EC proliferation and migration and increasing vascular permeability. VEGFB, which also binds to VEGFR1, plays a role in cell survival and indirectly promotes VEGFA induced angiogenesis (Lal, Puri, & Rodrigues, 2018) .
VEGFC is another critical player in VEGF signaling. This protein, which signals through the receptors VEGFR-3 and VEGFR-2, plays a key role across species, guiding both lymphatic and blood vasculature development and remodeling (Gore et al., 2011; Hogan, Bos, et al., 2009; Karkkainen et al., 2004; Kuchler et al., 2006; Lohela et al., 2009; Shin et al., 2016; Villefranc et al., 2013; Yaniv et al., 2006) . VEGFC is expressed by endothelial and non-endothelial cells, thus acting via both autocrine and paracrine signaling (Covassin, Villefranc, Kacergis, Weinstein, & Lawson, 2006; Helker et al., 2013; Khromova, Kopnin, Rybko, & Kopnin, 2012; Kodama et al., 2008; Lohela, Helotera, Haiko, Dumont, & Alitalo, 2008; Villefranc et al., 2013) . Evidence for its necessity for proper lymph formation is revealed by the finding that ectopic expression of VEGFC in mouse ear or skin keratinocytes results in hyperplasia of lymphatic vessels. Similarly, mice and zebrafish lacking VEGFC fail to develop a lymphatic vasculature as initial sprouting and directed migration of lymphatic progenitors from the cardinal vein are arrested (Karkkainen et al., 2004; Kuchler et al., 2006; Shin et al., 2016; Villefranc et al., 2013; Yaniv et al., 2006) . In addition to its predominant role in lymphangiogenesis, VEGFC was shown to induce angiogenesis upon overexpression in the mouse cornea, skin or ischemic hindlimb. Moreover, coronary vessel development is VEGFC dependent, and hearts devoid of VEGFC reveal dramatic delay in the formation of subepicardial sprouts (H. I. Chen et al., 2014) . Recently, it has been shown by in vitro studies that the let-7a/TGFBR3 axis regulates angiogenesis through transcriptional regulation of VEGFC (Wang et al., 2019) .
VEGFC has a critical role not only during development but also during tumor progression. In various human cancers, enhanced expression of VEGFC and higher levels of VEGFC in serum are commonly associated with tumor aggressiveness and lymph-node metastasis (Lohela et al., 2009; Su et al., 2007) . In esophageal carcinoma, for instance, angiogenesis is driven via the phosphoinositide-phospholipase C-ε (PI-PLCε)/NF-κB signaling pathway by direct promotion of VEGFC transcription (Y. Chen et al., 2019) . In xenograft or transgenic tumor models, stimulation of lymphangiogenesis by VEGFC promotes malignant cell dissemination (Stacker et al., 2014) . Furthermore, blockade of VEGFC expression in tumor cells by stably transfected small interfering RNAs reduces lymphangiogenesis and lymph node metastasis of murine mammary cancers. Similarly, soluble VEGFR-3 protein has been shown to inhibit VEGFC-induced tumor lymphangiogenesis and metastatic spread in a breast cancer mouse model (Wissmann & Detmar, 2006) .
A series of environmental and cellular factors were shown to modulate VEGFC expression.
For instance, Interleukin-6 (IL-6) and interleukin-17 (IL-17) regulate VEGFC expression via the PI3K-Akt or ERK 1/2 pathways, whereas MicroRNA-1826 significantly down-regulates VEGFC expression in human bladder cancer (J. C. Chen, Chang, Hong, Yu, & Su, 2012) .
Vegfc mRNA levels are heightened in the adipose tissue of obese mice, pointing to adipocytes as a source of elevated VEGFC levels in obesity (Karaman et al., 2015) . In adults, inflammation induces robust upregulation of VEGFC expression by macrophages (Baluk et al., 2005) . Additionally, various hormones, transcription factors, metallothioneins and microenvironmental stresses (e.g., hyperthermia, oxidative stress, high salt) were shown to control VEGFC expression (J. C. Chen et al., 2012; Cohen et al., 2009; Gauvrit et al., 2018; Machnik et al., 2009; Sapoznik et al., 2009; Schuermann, Helker, & Herzog, 2015) .
Here, we report that BACH transcription factors, which are known to be involved in various intracellular signaling pathways, modulate VEGFC expression during embryonic development and tumor progression, offering a better understanding of blood and lymph vessel formation during physiological and pathological conditions.
Results

Spatial and temporal expression of bach2 during zebrafish development
In order to explore the molecular mechanisms governing VEGFC expression, we searched for genes that co-express with VEGFC in human prostate cancer datasets (Glinsky, Glinskii, Stephenson, Hoffman, & Gerald, 2004) . We identified 434 genes, on which we further applied the Promoters of Clusters (POC) analysis (Tabach et al., 2007) . This method screens the promoters of genes with shared biological function against a library of transcription factor binding motifs and identifies those which are statistically over-represented. Five factors passed the basic significance threshold, out of which only two possessed binding sites within the VEGFC promoter. We then searched for evolutionarily conserved regions, which often represent potential DNA regulatory elements (Ovcharenko, Nobrega, Loots, & Stubbs, 2004) . Comparison of the VEGFC promoters of human, mouse and zebrafish revealed two highly conserved BACH (BTB and CNC homology) binding sequences ( Figure 1A) .
The BACH family of transcription factors comprises two members, BACH1 and BACH2. In mammals, BACH1 is expressed ubiquitously and has been shown to act either as an activator or repressor of transcription and to be involved in oxidative stress, metabolism, cell transformation, neurodegenerative diseases, tumor expansion and metastatic spread (Igarashi its loss is associated with severe autoimmune diseases. BACH proteins are highly conserved in vertebrates, particularly in the functional (BTB and bZip) domains and the regions immediately surrounding them (Igarashi & Watanabe-Matsui, 2014) . Zebrafish have four bach genes with homology to mammalian BACH: bach1a, bach1b, bach2a and bach2b (Fuse, Nakajima, Nakajima-Takagi, Nakajima, & Kobayashi, 2015; Luo et al., 2016; Zhang et al., 2014) .
As a first step, we evaluated the expression pattern of the different bach transcripts in ECs isolated by Fluorescence-Activated Cell Sorting (FACS) from Tg(fli1:EGFP) y1 (Lawson & Weinstein, 2002) zebrafish embryos (L. . We found the transcripts of bach2a and bach2b to be more abundant than bach1b, while bach1a is barely detectable in the GFP-positive (GFP + ) cell population, at either 21-24 hours post-fertilization (hpf) or 3 days post fertilization (dpf) ( Figure 1B ). Consequently, we focused our studies on bach2a and bach2b, as they are the major paralogs expressed in the endothelium. To assess the spatial and temporal expression patterns of bach2a and bach2b during zebrafish embryogenesis, we performed whole-mount in situ hybridization (WISH). Abundant expression of bach2a and bach2b was apparent in the somites and somite boundaries at 20 hpf and up to 48 hpf ( Figure 1C ). Furthermore, we detected strong enrichment of bach2a transcripts in myotomes and in several areas of the central nervous system (CNS), including the hindbrain, midbrain-hindbrain boundary, midbrain and forebrain (Figure 1-figure supplement 1).
Figure 1
Spatial and temporal expression of bach2 paralog transcripts during zebrafish development.
(A) BACH putative binding sites are evolutionary conserved in the VEGFC promoter region. Numbering is from the ATG (translation initiation) due to the difference in length of the mouse's 5' UTR. An arrow indicates Transcription Start Site (TSS), and the location of the first exon is marked as a gray rectangle. The location of the BACH sites is as predicted by Genomatix Genome Analyzer MatInspector: Human (NM_005429.4 TSS at hg19, chr4:177713899 on the minus strand); Mouse (NM_009506.2 TSS at mm9, chr8:54077532 on the plus strand); Zebrafish (NM_205734.1 TSS at Zv9, chr1:39270725 on the minus strand). (B) Semi-quantitative RT-PCR analysis of the indicated genes in enriched GFP + cells isolated by FACS from Tg(fli1:EGFP) y1 embryos at two developmental time points, 21-24 hpf and 3 dpf (two independent experiments for each time point). (C) A lateral view of the trunk region of a wild-type zebrafish embryo at 20, 24, 30 and 48 hpf, detected with a specific bach2a or bach2b anti-sense mRNA probe. A red arrowhead indicates somite boundaries. Scale bar, 100 µm. Embryos at 20 (A), 24 (B), 30 (C, D) and 48 (E) hpf were examined by whole-mount in situ hybridization with an antisense bach2a riboprobe. Abbreviations: FB, forebrain; S, somite; TE, telencephalon; MB, midbrain; MHB, midbrain hindbrain boundary; HB, hindbrain; rHB, rostral hindbrain; SB, somiteboundaries; M, myotomes; OT, optic tectum. Scale bar, 500 µm.
bach2a is essential for developmental angiogenesis and lymphangiogenesis
We then assessed the contribution of BACH to angiogenesis and lymphangiogenesis during embryonic development and, specifically, investigated their putative role as regulators of vegfc expression and function during zebrafish vasculature formation. We used antisense morpholino oligonucleotides (MOs) to knockdown the expression of the two bach2 paralogs and then surveyed the phenotypic changes at different stages of development. At 30 hpf, clear defects were observed in the primordial hindbrain channel (PHBC) in bach2a MO-injected Tg(fli1:EGFP) y1 zebrafish embryos (Figures 2A and 2B) . Similar phenotypes were detected in vegfc morphants (Figures 2A and 2B) , in line with previous reports demonstrating impaired PHBC formation following the blocking of Vegfc-activated Vegfr3 signaling (L. D. Hogan, Herpers, et al., 2009; Schuermann et al., 2015; Shin et al., 2016; Villefranc et al., 2013) . In contrast to bach2a downregulation, no defects were detected in Tg(fli1:EGFP) y1 embryos either injected with different concentrations of resembling the phenotypes observed in collagen and calcium-binding EGF domain-1 (ccbe1) (Hogan, Bos, et al., 2009 ) and vegfc (Karkkainen et al., 2004; Shin et al., 2016) mutants. In contrast, no morphological abnormalities were observed following bach2b knockdown
To confirm the specificity of the bach2a morphant phenotype, we generated bach2a mutants using CRISPR/Cas9-mediated gene editing (Figure 2-figure supplement 2C-2E). To our surprise, homozygous bach2a mutants displayed no primordial hindbrain channel defects (bach2a mut-/-, Figures 2D and 2E ). We therefore hypothesized that genetic compensation (El-Brolosy et al., 2019; El-Brolosy & Stainier, 2017; Rossi et al., 2015) through activation of bach2b could potentially account for the absence of angiogenic phenotypes in bach2a mutants. To address this possibility, we mated bach2a +/carriers and injected their progeny with either a sub-dose of bach2b MO or with bach2b gRNA that does not induce vascular malformations in WT embryos (Figures 2A-2C ). Interestingly, PHBC formation defects were identified in ~25% of the embryos, which upon genotyping were found to carry the bach2a mutation (bach2a mut-/-+ bach2b MO and bach2a mut-/-+ bach2b gRNA, Figures 2D and 2E) , as opposed to their wild-type siblings (bach2a mut+/+ + bach2b MO and bach2a mut+/+ + bach2b gRNA, Figure 2E ). Conversely, following bach2a MO injection, bach2a wild-type siblings displayed PHBC formation defects while homozygous mutants appeared normal (Figures 2D and 2E) , suggesting that the bach2a mut-/mutants were less sensitive than their bach2a mut+/+ siblings to bach2a MO injections, and further confirming the specificity of both mutants and morphants. In order to ascertain whether the compensation mechanism involves upregulation of the paralogous bach2b gene, we assessed its expression in wild-type and bach2a mutants, Representative genotyping PCR of a wild-type (WT) and a CRIPSR/Cas9-mediated homozygous bach2a knockout (bach2a mut-/-) Tg(fli1:EGFP) y1 embryo using primer sets which flank the gRNA cut sites. Arrows indicate the lengths of the resultant DNA fragments. (E) PCR-sequencing chromatograph of the bach2a locus in a Tg(fli1:EGFP) y1 embryo (WT) aligned with a homozygous bach2a knockout (bach2a mut-/-). CRIPSR/Cas9-mediated genome modification at the zebrafish bach2a locus leads to the deletion of five base-pairs, which causes a frame shift in the protein sequence (translation shown below the DNA sequence). A stop codon (indicated by a dot in the translation) created 17 amino acids downstream of the deletion site, leading to the formation of a 57-aminoacid-long, truncated protein. (F) Quantitative RT-PCR validation of bach2b expression conducted for wildtype (bach2a mut+/+ ) and homozygous (bach2a mut-/-) 6-dpf siblings obtained from F2 bach2a intercross. Error bars, mean ± s.e.m.; P=0.2466 (two independent experiments consisting of twenty single larvae in each group). (G) Semi-quantitative RT-PCR analysis of bach2a expression in wild-type (bach2a mut+/+ ) and homozygous (bach2a mut-/-) 6-dpf siblings obtained from F2 bach2a heterozygous intercross. We then asked whether bach2a is also involved in lymphatic vessel development. To answer this question, we analyzed the effects of bach2a down-regulation on the formation of parachordal cells (PACs), the building blocks of the thoracic duct (TD) and the trunk lymphatic system in zebrafish (Nicenboim et al., 2015; Yaniv et al., 2006) . A significantly reduced number of PAC-containing segments was detected in bach2a MO-injected Similarly, 87% of vegfc morphants were devoid of a TD ( Figures 4A and 4C ), as previously reported (Shin et al., 2016; Villefranc et al., 2013) . In contrast to bach2a morphants, downregulation were more pronounced than those caused by the loss of vegfc, possibly due to the involvement of bach2a in additional signaling pathways . Confocal projection of the trunk region showing PAC-containing segments in Tg(fli1:EGFP) y1 -homozygous bach2a mutants (bach2a mut-/-) from F2 bach2a mut+/incross. An asterisk indicates the absence of PACs in bach2a mut-/embryos injected with bach2b MO (bach2a mut-/-+ bach2b MO) or bach2b gRNA (bach2a mut-/-+ bach2b gRNA) and a white arrow, their presence. Scale bar, 100 µm. (G) Number of PAC-containing segments (mean ± s.e.m.) in 3-dpf embryos randomly selected from bach2a +/-F2 incross progeny injected with control MO (10 ng, nbach2amut + Control MO = 50; P=0.5514), bach2a MO (3.75 ng, nbach2amut + bach2a MO = 75; *P<0.0001), bach2b Mo (3.75 ng, nbach2amut + bach2b MO = 55; *P and **P<0.0222) or bach2b gRNA (125 ng, nbach2amut + bach2b gRNA = 137; *P and **P<0.0001 ). Following genotyping, offspring followed the expected Mendelian ratios of inheritance. Rossi et al., 2015) .
BACH1 promotes angiogenesis and lymphangiogenesis during tumor expansion in mouse models
In light of the perception that cancers frequently reactivate embryonic developmental signaling cascades to promote their expansion and aggressiveness, resulting in metastasis and poor patient outcome, we decided to evaluate the contribution of BACH to vascular remodeling during tumor progression. Emerging evidence point to BACH1, a ubiquitously expressed protein, as a tumor-promoting factor that acts via multiple intracellular signaling cascades (Alvarez & Woolf, 2011; Yun et al., 2011) . Recently, higher levels of BACH1 were found to be associated with poor prognosis in human ovarian cancer and to promote lung cancer metastasis (Lignitto et al., 2019; Wiel et al., 2019) . BACH1 has been established as a major regulator of breast cancer bone metastasis (Liang et al., 2012) and was postulated as a potential novel therapeutic candidate for cancer treatment ( Numerous reports suggest that, in addition to blood vessel formation, lymphangiogenesis and lymphatic vessel remodeling are pivotal events for tumor expansion and metastatic spread (Stacker et al., 2014) . We thus examined the effects of BACH1 on the lymphatic vasculature in various mouse tumor models. To gain insight into the 3D complexity of the lymphatic network within intact tumors, we subjected ES2 subcutaneous xenografts to a modified CLARITY (Clear, Lipid-exchanged, Anatomically Rigid, Imaging-compatible, Tissue hYdrogel) technique (K. Chung et al., 2013; Hama et al., 2011; Oren et al., 2018) Expansion of the lymph vessels in the diaphragms of BACH1-overexpressing tumors was associated with increased cell infiltration (arrow, Figure 5D ). Co-immunofluorescence using antibodies directed against LYVE1 and Cytokeratin 7, an antigen expressed in ES2 cells (Stimpfl et al., 1999) , revealed that the metastasizing cells originated from the transplanted ES2 tumor cells (arrow, Figure 5F ). This potential of BACH1 to promote tumor cell invasion was further confirmed by an in vitro invasion assay demonstrating a ~two-fold increase in the invasion abilities of BACH1-overexpressing as compared to control ES2 cells ( Figures   5G and 5H) . These data indicate that in mouse models BACH1 remodels vascular architecture and promotes metastatic spread of tumor cells via the lymphatic vessels.
Figure 5
BACH1 promotes angiogenesis and lymphangiogenesis during ovarian tumor progression in mouse models. A movie demonstrating the lymphatic vessel density in a control subcutaneous ES2 ovarian carcinoma xenograft subjected to LYVE1 immunofluorescence staining along with a modified CLARITY technique. Scale bar, 100 µm.
Figure 5-Movie 2
Lymphatic vessel complexity in a BACH1-overexpressing tumor.
A movie demonstrating the lymphatic vessel density in a subcutaneous-BACH1-overexpressing ES2 ovarian carcinoma xenograft subjected to LYVE1 immunofluorescence staining along with a modified CLARITY technique. Scale bar, 100 µm.
BACH and VEGFC are functionally linked
Next, we investigated the molecular mechanisms underlying BACH activity. Since BACH proteins can directly bind to the promoter of their target genes (Ogawa et al., 2001; Warnatz et al., 2011; Yun et al., 2011) , we assessed the ability of the binding sites in the VEGFC promoter region identified in silico ( Figures 1A and Figure 6A ) to interact with BACH.
Chromatin immunoprecipitation (ChIP) was performed on human ovarian clear cell carcinoma ES2 cells, overexpressing BACH1 tagged with a human influenza hemagglutinin (HA) tag ( Figure 5-figure supplement 1A) . We observed that specific sequences from both proximal and distal regulatory regions were enriched in the presence of antibodies against either HA or BACH1, indicating that both sites are transcriptionally functional ( Figure 6B ).
To investigate the functional significance of two potential BACH binding sites, promoterreporter constructs were engineered with deletion of the BACH binding sites, either separately or concurrently. Disruption of the proximal site led to a 23% increase in VEGFC basal promoter activity ( Figures 6C and 6D) , supporting an inhibitory role. In contrast, deletion of the distal binding site individually or in combination with the proximal site resulted in an 86% reduction in VEGFC basal promoter activity ( Figures 6C and 6D ), suggesting a pivotal role in basal promoter functioning. Additionally, overexpression of BACH1 in human ovarian ES2 carcinoma cells induces a significant increase in VEGFC expression ( Figure 6E ), strongly supporting a genetic and functional link between these two factors. To investigate whether these results are recapitulated in vivo, we analyzed the effect of bach2a knockdown on vegfc expression during zebrafish development. A marked downregulation of vegfc expression was observed in bach2a morphants ( Figure 7A ). This effect was specific for bach2a, as vegfc expression remained intact in bach2b MO-injected embryos (Figure 7-figure supplement 1) . We then attempted to rescue the phenotypes of bach2a morphants by overexpressing vegfc mRNA. Co-injection of in vitro transcribed vegfc mRNA and bach2a MO partially restored PHBC formation at 30 hpf ( Figures 7B and 7C) .
Similarly, the number of PAC-containing segments increased by approximately 50%
following co-injection of bach2a MO and vegfc mRNA (Figures 7D and 7E ) and a two-fold recovery in TD formation was detected ( Figures 7F and 7G ). In addition, pericardial and body edema, as well as reduced blood flow, were partially restored following an injection of vegfc mRNA (Figure 7-figure supplement 2) .
Finally, we addressed the molecular basis of the BACH1 and VEGFC interaction during 
The expression of BACH1 and VEGFC correlates during human cancer progression
Metastatic spread of cancer cells from primary solid tumors to sentinel lymph nodes and distant tissues and organs is one of the hallmarks of malignant neoplasms (Valastyan & Weinberg, 2011) , responsible for the majority of human cancer-related deaths. Neoplastic cell dissemination may occur either via blood vessels or via the lymphatic system (Paduch, 2016) . VEGFC is one of the key factors promoting malignant cell spread, as demonstrated both in mouse tumor models (Ma et al., 2018; Mandriota et al., 2001; Skobe et al., 2001) and during human cancer progression (J. C. Chen et al., 2012; H. Jiang, Shao, & Zhao, 2014; Rinderknecht & Detmar, 2008; Thiele & Sleeman, 2006) . Similarly, it was shown that BACH1 promotes the metastasis of breast cancer through different molecular mechanisms (J. Lee et al., 2014; U. Lee et al., 2013; Liang et al., 2012) and its stabilization in lung adenocarcinoma is associated with increased metastatic dissemination and poor survival (Lignitto et al., 2019; Wiel et al., 2019) . To substantiate the pathophysiological relevance of the interaction between BACH1 and VEGFC, we carried out an in silico analysis of publicly available gene-expression data generated by The Cancer Genome Atlas (TCGA) Research Network (https://cancergenome .nih.gov/). We analyzed RNA-sequencing-derived data regarding aberrant gene expression in specimens taken from melanoma and lung adenocarcinoma (LUAD) human cancer patients. Melanoma is one of the commonest forms of skin cancer, while LUAD is at present the most common lung cancer subtype among nonsmokers. In both cancers, while the early-stage is curable by surgical resection, lymphatic metastasis results in poor prognosis. Interestingly, we found that BACH1 expression positively and significantly correlates with the expression of VEGFC in human melanoma and LUAD cancer progression (Figure 8 ). Specifically, BACH1 and VEGFC expression are significantly higher in samples from melanoma patients clinically diagnosed with lymph node metastatic spread, as compared to those with primary tumors ( Figure 8A) . Similarly, the expression of BACH1 and VEGFC were significantly augmented in specimens derived from clinical stage III LUAD patients in comparison to stage I and II ( Figure 8B ). According to the tumor node metastasis (TNM) taxonomy classification, stage I refers to the early, nonmetastatic stage, while stages II and III usually indicate the intermediate, regional lymphatic metastatic stages, of which stage III has a higher lymphatic metastasis degree than stage II.
This correlation may indicate the potential ability of BACH1 and VEGFC to promote cellular migration and cancer invasion. Hence, BACH1 and VEGFC may serve as candidate diagnostic biomarkers in cancer patients.
Figure 8
The 
Discussion
VEGFC is a potent regulator of the growth and maintenance of blood and lymphatic vessels during embryonic development, tumor expansion and metastasis. The results presented here demonstrate that members of the BACH family regulate VEGFC expression, thereby promoting angiogenesis and lymphangiogenesis during zebrafish development and in ovarian and lung mouse tumor models.
BACH1 and BACH2 are important for the homeostasis of heme, an essential molecule for many biological functions (Igarashi & Watanabe-Matsui, 2014; Warnatz et al., 2011) .
Imbalanced levels of heme can cause oxidative stress when it reacts with molecular oxygen, which in turn disrupts various cellular signaling pathways. BACH1 was initially discovered as a physiological repressor of heme oxygenease-1 (HO-1), a rate-limiting enzyme in heme catabolism stimulated by Nuclear factor erythroid 2-related factor 2 (NRF2) (Warnatz et al., 2011) . Recent emerging evidence, however, indicate the widespread functions of BACH1 in diverse physiological and pathological settings, including hematopoiesis, inflammation, cardiovascular disease, aging, metabolic disorders and neurodegenerative diseases. BACH2
was established as a crucial factor for B and T cell memory differentiation. Nevertheless, the potential roles of these transcription factors during embryogenesis remain obscure (Sidwell & Kallies, 2016) . Members of the BACH family possess both a BTB/POZ and a CNC-bZip functional domain, conferring them with protein-protein interaction and DNA-binding capabilities to the antioxidant response elements (ARE) . The BTB/POZ domain, located at the N-terminus, mediates dimer formation (Igarashi & Watanabe-Matsui, 2014) . Conversely, the bZip domain enables DNA binding and the formation of heterodimers with small musculoaponeurotic fibrosarcoma (sMaf) transcription factors (Davudian, Mansoori, et al., 2016) . Three evolutionary conserved sMafs have been identified in mammals and an additional one in zebrafish, all displaying complex expression patterns during embryogenesis (Yamazaki, Katsuoka, Motohashi, Engel, & Yamamoto, 2012) . While single sMaf knockout mice show no or a mild phenotype, triple-knockout embryos display severe growth retardation and liver hypoplasia, resulting in embryonic lethality at E13.5 (Yamazaki et al., 2012) . Interestingly, a member of the large Maf family of transcription factors, mafba in zebrafish (Koltowska et al., 2015) and Mafb in mice (Dieterich et al., 2015) , was shown to be activated by VEGFC. In zebrafish, mafba is crucial for the migration of lymphatic precursors after their initial sprouting from the cardinal vein (Koltowska et al., 2015) . In lymphatic endothelial cells (LECs), MAFB promotes the expression of PROX1, KLF4, NR2F2, and SOX18, key transcription factors and markers of differentiated LECs. Furthermore, E14.5 Mafb −/− mouse embryos show impaired lymphatic patterning in the skin (Dieterich et al., 2015) . Altogether, these studies suggest that the BACH and MAF transcription factor families play key roles during lymphangiogenesis.
Uncovering the complexity within these molecular networks may be exploited for the understanding of EC differentiation and vascular development.
Four bach genes (bach1a, bach1b, bach2a and bach2b) with homology to mammalian BACH are present in the zebrafish genome. Phylogenetic analysis indicates that bach1a, bach1b and bach2a, bach2b belong to two distinct groups, bach1 and bach2, respectively, with bach2 possibly diverging earlier than bach1 (Luo et al., 2016) . It was shown that, during embryogenesis, the two bach1 genes inhibit heme oxygenase 1a (hmox1a) induction in zebrafish (Fuse et al., 2015) . In a recent study, overexpression of bach1b was found to suppress developmental angiogenesis by inhibiting Wnt/β-catenin signaling (L. Jiang et al., 2017) . Herein, we show that the bach2a gene controls vegfc expression, directing blood and lymphatic vascular development in zebrafish. Yet, the lack of full overlapping expression between bach2a and vegfc supports additional tissue-specific functions for each of these factors.
Accumulating data establish BACH1 as a critical facilitator of tumorigenesis and metastasis in breast (U. Lee et al., 2013) , colon (Davudian, Shajari, et al., 2016) , prostate (Shajari et al., 2018) ovarian and lung (Lignitto et al., 2019; Wiel et al., 2019) cancer.
Elevated levels of BACH1 expression have been linked to a higher risk of breast cancer recurrence in patients (Liang et al., 2012) , while association with metastatic spread and poorer prognosis has recently been suggested in the case of human ovarian cancer and lung adenocarcinoma (Lignitto et al., 2019; Wiel et al., 2019) . Ectopic expression of BACH1 in breast cancer cells promotes malignancy and metastasis, while its knockdown suppresses these processes. BACH1 has been placed downstream of the Raf kinase inhibitory protein (RKIP), a tumor suppressor gene shown to inhibit invasion and bone metastasis in a breast cancer xenograft mouse model (U. Lee et al., 2013; Yun et al., 2011) . Inactivation of RKIP during tumor expansion results in higher expression of BACH1 and its target genes C-X-C chemokine receptor type 4 (CXCR-4) and matrix metalloproteinase1 (MMP1), established drivers of tumor progression and metastasis (Foley & Kuliopulos, 2014; Mishan, Ahmadiankia, & Bahrami, 2016) . Furthermore, ablation of BACH1 in human colon carcinoma (Davudian, Shajari, et al., 2016) or in prostate cancer cells (Shajari et al., 2018) , prevents cell growth, migration and invasion in vitro, decreasing the expression of its main metastasis-related genes, MMP1, let-7a and CXCR4. Interestingly, cxcr4 is expressed in the somites and the endothelium of zebrafish embryos (Chong, Emelyanov, Gong, & Korzh, 2001) , where we detect the expression of both bach2a and bach2b transcripts. cxcr4 was shown to be crucial for lateral aortae formation (Siekmann, Standley, Fogarty, Wolfe, & Lawson, 2009 ) and trunk lymphatic vascular network assembly (Cha et al., 2012) and a key modulator of vascular progenitor cells (Sainz & Sata, 2007) . In addition to its contribution to development, CXCR4 was shown to play a role in carcinogenesis, tissue repair and other pathological circumstances (Kawaguchi, Zhang, & Nakanishi, 2019) . VEGFC can thus be added to a growing list of tumor and metastatic proteins, including CXCR4 and MMP1, all of which are transcriptionally regulated by BACH1. Including VEGFC as a target of BACH1 allows novel perspectives of the role of BACH1 in vascular development during embryogenesis and pathological conditions.
During the past years, a substantial amount of in vitro, animal and small-size human studies established BACH proteins as a hub of critical transcriptional networks that govern key processes during normal physiology and disease states. Surprisingly, however, Bach single- (Muto et al., 2004; Sun et al., 2002) or double- (Ebina-Shibuya et al., 2016) knockout mice exhibit no phenotype at birth. This may result from the existence of a yet unknown compensatory mechanism similar to the one described here in zebrafish. Further understanding the mechanisms underlying BACH's mode of action during embryogenesis, adult life and tumorigenesis would pave the way to resolving this ambiguity.
Altogether, our results highlight BACH as a novel regulator of angiogenesis and lymphangiogenesis during embryonic development as well as tumor progression. We show that BACH controls the expression of VEGFC, an established pro-lymphangiogenic and angiogenic growth factor. The expanded recognition of BACH1 activity, together with its inhibitory effect on NRF2, an important detoxifying and antioxidant factor, mark it as a potential therapeutic target. Hence, various direct or indirect promising BACH1 modulators have been developed (Arbiser, 2011; Banerjee, Basu, Arbiser, & Pal, 2013; Cuadrado et al., 2019) . Accordingly, recent reports demonstrated that targeting of BACH1 and mitochondrial metabolism may serve as an effective therapy for triple negative breast cancer (J. Lee et al., 2019) . In two new studies on lung cancer it was shown that therapeutic intervention that either destabilizes BACH1 (Lignitto et al., 2019) or disrupts its ability to induce glycolysis (Wiel et al., 2019) have the potential to inhibit BACH1 pro-metastatic activity. Targeting the BACH1/VEGFC signaling axis with these inhibitors may potentially be significant therapeutically for various blood and lymphatic vessels pathologies as well.
Experimental Procedures
Bioinformatics analysis
Transcription factor binding site analysis was performed using the Genomatix Genome Analyzer (Genomatix Software GmbH, Germany) MatInspector program (Cartharius et al., 2005) . Promoter regions of the human, mouse and zebrafish Vegfc genes were extracted from the UCSC genome browser (Kent et al., 2002) as follows: Human-GRC37/hg19 chr4: 177, 713, 716, 211; 075, 077, 946; Zebrafish Zv9/danRer7 chr1:39, 270, 273, 225 . The zebrafish bach sequences used are: bach1a: NM_001040313; bach1b: NM_001020663; bach2a: XM_680223 and bach2b:
XM_677841.
Zebrafish lines and husbandry
The EK and Tg(fli1:EGFP) y1 (Lawson & Weinstein, 2002) zebrafish lines were maintained under standard conditions (Isogai, Lawson, Torrealday, Horiguchi, & Weinstein, 2003) . All experiments were carried out according to the guidelines of the Weizmann Institute Animal
Care and Use Committee.
Fluorescence Activated Cell Sorting (FACS) and RT-PCR analysis
Tg(fli1:EGFP) y1 embryos at 21-24 hpf and 3 dpf were collected and dissociated as previously described (Nicenboim et al., 2015) . 
Construction of the pCS2vegfcCDS plasmid
The full-length coding region of zebrafish vegfc was amplified from cDNAs derived from 24 hpf embryos using a forward (5'-ATGCACTTATTTGGATTTTCT) and a reverse (5'-TTAGTCCAGTCTTCCCCAG) primers, and sub-cloned into the pCRII-TOPO cloning vector (Invitrogen). Following nucleotide sequence verification, a Gateway-compatible (Invitrogen) middle entry clone was generated using Gateway BP clonase (Invitrogen) mediated recombination. A pCS2vegfcCDS plasmid was produced using Gateway LR clonase (Invitrogen). Capped mRNA was transcribed from a Not1-linearised template using the mMessage mMachine Kit (Ambion).
Microinjection of zebrafish embryos
Morpholino antisense oligonucleotides (Gene Tools) were designed with sequences complementary to zebrafish bach2a and bach2b cDNA in a location downstream to the initiating start codon. The morpholino sequences were as follow: bach2a: (GenBank accession number XM_680223.4), 5'-TGTCAGGCTTCTCCTCCATAGACAT-3' and bach2b: (GenBank accession number XM_677841.2), 5'-CTTCAGACTTCTCATCCA CGGACAT-3'. The morpholino targeting the zebrafish vegfc was previously described (Yaniv et al., 2006) . As a control the Gene Tools standard control MO (5'-CCTCTTAC CTCAGTTACAATTTATA-3') was applied. Specific Morpholino oligonucleotides were injected into one-cell stage embryos at concentrations from 3.75 up to 10 ng and control MO at 10 ng per embryo. For rescue experiments pCS2vegfcCDS mRNA (800 pg per embryo) was simultaneously injected with the morpholino (3.75 ng per embryo). For quantification of the phenotypes, embryos from each group were randomly selected.
Quantification was deduced from pools of at least 3 independent experiments.
Design and synthesis of guide RNA (gRNA)
The design of the bach2a and bach2b CRISPR guide was performed with CHOPCHOP (Montague, Cruz, Gagnon, Church, & Valen, 2014) (chopchop.rc.fas.harvard.edu) .
Potential off-target sequences were checked using the MIT CRISPR Design site (crispr.mit.edu) (Hsu et al., 2013) . Oligonucleotides synthesized for the guide sequence 5'-GGACGTCCTGTGTGACGTGA and 5'-CTGTGCCGAATTCCTGCGCA for bach2a and bach2b respectively, were cloned into the BsmBI site of the pT7-gRNA plasmid (a gift from Wenbiao Chen) (Addgene plasmid # 46759) (Jao, Wente, & Chen, 2013) . Alt-R S.p.
Cas9 Nuclease 3NLS (250 ng/µl, Integrated DNA Technologies) and gRNA (125 ng/µl) in 5 µl total volume were co-injected into one-cell-stage Tg(fli1:EGFP) y1 embryos. To detect mutagenic events, DNA was extracted from 24 hpf embryos, amplified using a set of primers 5'-AGCAAGGAATGTCTATGGAGGA and 5'-ATGAGTGGCTCGTGT TCTGTC (235bp) for bach2a and 5'-CGCTCCATTGTT ACAGTTTGC and 5'-GCCG TCCTCTTCACTGCGC (157 bp) for bach2b. PCR products were separated on 3.5%
MetaPhor Agarose gel (Lonza). When both genotyping and phenotypic analyses of single zebrafish embryos from heterozygous bach2a intercross was needed, the larval tail (6 dpf) was used for genotyping, whereas RNA was extracted from the anterior part using NucleoSpin RNA plus XS RNA purification kit (Macherey-Nagel).
Whole-mount in situ Hybridization
Embryos were dechorionated and fixed overnight in 4% PFA at 4°C, at the appropriate time points. In situ hybridization was performed as previously described (Yaniv et al., 2006) using single-stranded digoxygenin-dUTP-labeled RNA probes transcribed by T7 RNA polymerase (Roche). The PCR generated probes were amplified with the following set of Tween-20 (PBST). For tissue clarification embryos were mounted in glycerol and imaged using Leica M165 FC stereomicroscope.
Cell culture
Human ovarian clear cell carcinoma ES2 cell line (American Type Culture Collection) was cultured in DMEM supplemented with 10% fetal bovine serum (FBS). Mouse D122 Lewis lung carcinoma cell line (Eisenbach et al., 1984) , kindly provided by Prof. Lea Eisenbach,
Weizmann Institute of Science, Israel) was grown in DMEM containing 10% FBS, 1 mM sodium pyruvate and 1% nonessential amino acids. All cell lines were routinely tested for mycoplasma contamination using the EZ-PCR Mycoplasma Test Kit (Biological Industries).
Establishment of stable BACH1-overexpressing cell pools
Full-length coding region of the human BACH1 (BACH1, GenBank accession number NM_206866) and mouse Bach1 (Bach1, GenBank accession number BC057894.1) with an N-terminal hemagglutinin (HA) tag were reverse transcribed with SuperScript III Reverse Transcriptase (Invitrogen) and PCR-amplified using Phusion high-fidelity DNA polymerase (New England Biolabs) together with the following set of primers: BACH1: 5'-ATGTCTCTGAGTGAGAACTCGG and 5'-TTACTCATCAGTAGTACATTTATC;
Bach1: 5'-ATGTCTGTGAGTGAGAGTGCG and 5'-TTACTCGTCAGTAGTGCACTTG.
The fragments were ligated into pCRII-TOPO and their sequence fidelity was confirmed by sequencing. Inserts were restricted and ligated into pEIRES expression vector containing the human EF-1a promoter (Hobbs, Jitrapakdee, & Wallace, 1998) to produce the pIRESBACH1 and pIRESBach1 constructs. ES2 and D122 cells were transfected with pIRESBACH1 and pIRESBach1 expression vectors respectively, using Lipofectamine 2000 reagent (Invitrogen) and selected with 2.5µg/ml puromycin (Sigma) as was previously described ). An average of 50 individual puromycin-resistant colonies were collected together and BACH1-overexpression was confirmed by immunoblotting.
ES2 and D122 cells that were stably transfected with the pEIRES empty vector were used as controls.
Chromatin immunoprecipitation (ChIP) assay
The ChIP experiments were performed using the ChIP-IT-Express kit (Active Motif catalog no. 53009). Cells were fixed and cross-linked using 1% formaldehyde at room temperature for 10 min. Fixation was stopped by adding glycine. DNA extracted from nuclear fraction was subjected to enzymatic shearing for 35 min at 37 o C to obtain mononucleosomes. The resulting chromatin preparation was immunoprecipitated with magnetic protein G coupled beads and 10 mg of either anti HA-tag (HA.11, Covance), Bach1 (Santa Cruz, sc-14700) or nonspecific-IgG antibody. DNA-protein crosslinking was reversed at 65 o C (4 h), treated with Proteinase K (2 h, 42 o C). The recovered DNA was then subjected to PCR using the following set of specific primers: BACH proximal site: 5'-GAGGGAGAGTGAGAGGGG and 5'-CGCAGGATCCTCCAGAGC; BACH distal site: 5'-CCGAGTCTGATGGGATGG AA and 5'-GCCTTTGTTGATACAGCCTTGG.
Transient transfection and Luciferase Assay
The 5′-regulatory region of human VEGFC gene (NG_034216.1) encompassing 2274 nucleotides (-1 to -2274 in relation to ATG, Figure 1) Membranes were probed with anti HA-tag monoclonal antibody (Covance, HA.11, 1:100) while b-Tubulin (Santa Cruz, H-235, 1: 500) was used as a loading control. Appropriate HRP-conjugated anti-mouse or anti-rabbit secondary antibodies (Jackson ImmunoResearch, 1:10,000) were used respectively.
Cell invasion assay
The invasion potential of the cells was examined in vitro using BioCoat Matrigel Invasion Chamber (Corning). A total of 80x10 3 cells suspended in serum-free medium were seeded in the upper chamber. To initiate cell invasion medium supplemented with 10% FBS was added as a chemoattractant in the low chamber. Cells were incubated at 37 o C for 20 h and invaded cells on the inferior surface of the inserts were fixed, washed, and stained with crystal violet (Sigma). Each assay was repeated two times in duplicates. For analysis the entire Matrigel surface area was imaged (Olympus SZX16 stereomicroscope, 2.5×magnification) and quantified using the ImageJ software. To ensure that the difference in invasion rate is not due to differential cell growth rate, total cell number validation was carried on a parallel plate. Cells were stained with crystal violet, lysed with 1% SDS, 0.1N NaOH solution followed by direct dye intensity measurement.
Tumor initiation, histologic preparation, immunohistochemistry and morphometric analysis Subcutaneous tumors were generated by injecting 2×10 Morphometric blood and lymphatic vessel coverage analysis were performed on CD-34 and LYVE1 stained tumor sections, respectively. Images of CD-34-stained sections were captured with a fluorescence microscope (NI-U, Nikon, Tokyo, Japan), equipped with Plan
Fluor objectives connected to CCD camera (DS-Ri1, Nikon). Digital images were collected and assembled using Adobe Photoshop (Adobe Systems). LYVE1 immunohistochemicalstained sections were scanned using the Panoramic Viewer. The density of vessels was evaluated using Image Pro Plus software (Media Cybernetics). For all analysis, investigators were blinded and unaware of group allocation. All animal experiments described in this study were performed according to the Guidelines the Weizmann Institute Animal Care and Use Committee. For immunostaining of ES2 cells, fixation was carried out in 4% paraformaldehyde for 10 minutes. Fixed cells were then blocked for unspecific staining in 0.3% Triton X-100, 10% horse serum for 90 min at RT, incubated with antibodies directed either against HA-tag (Sigma, 1:200) or VEGFC (Santa Cruz, H-190
Clearing and immunofluorescence staining
Excised tumors were fixed with 4% PFA for 1 week at 4°C, washed three times with phosphate-buffered saline (PBS), permeabilized with (0.2% Triton X-100 in PBS) for 4 h, and immersed overnight in blocking solution (PBS containing 0.05% Triton X-100 and 10% normal goat serum). For immunofluorescent staining tumors were incubated with primary mouse anti LYVE1 antibody (Fitzgerald Industries) diluted (1:250) in an antibody cocktail (50% blocking solution, 0.05% Triton X-100 in PBSX1) for 1week at 4°C, washed 24 h (1% blocking solution, 0.05% Triton X-100 in PBS), and probed with an Alexa fluor-594 conjugated goat anti rabbit secondary antibody (Molecular Probes -Life Technologies, A11037, 1: 250) diluted in antibody cocktail for an additional week at 4°C. Following 24 h wash, tumors were subjected to a Whole Organ Blood and Lymphatic Vessels Imaging (WOBLI) clearing procedure (K. Chung et al., 2013; Hama et al., 2011; Oren et al., 2018) .
Briefly, tumors were re-fixed with 4% PFA for 24-72h at 4°C, transferred to hydrogel solution (4% Acrylamide, 0.025% Bisacrylamide, 0.25% Va-044 and 4% PFA in PBS) for
1week and passively cleared (200 mM Boric acid and 4% SDS) for 2 weeks at 37°C.
Subsequently, tumors were placed in Scale solution (4M Urea, 10% Glycerol and 0.1% Triton X-100) for 48 h. A sequence of 3D images and movies were acquired using Zeiss LSM710 confocal microscope (Zeiss, Oberkochen, Germany).
Microscopy
Images were acquired on Zeiss LSM 780 upright confocal microscope (Carl Zeiss) with a W-Plan Apochromat ×20 objective, NA 1.0. Fluorescent proteins were excited with singlephoton laser (488nm). Alternatively, Leica TCS SP8 microscope, equipped with environmental control, 2 internal Hybrid (HyD) detectors and Acusto Optical Tunable Filter (Leica microsystems CMS GmbH, Germany) was used and excitation was done by using 488nm by Ar laser and emission was collected using the internal HyD detector at 510-625nm with gain of 100.
Statistical Analysis
Statistical analyses were performed with analytic computerized software ( Comparisons. Fisher's exact test analysis was used to compare proportional data.
Differences were considered significant at P < 0.05. Unless otherwise noted, data are presented as mean ± s.e.m.
